FAA grounds greater than 170 Boeing 737 Max 9s after Alaska Airways panel blows out

Passenger oxygen masks hang from the roof next to a missing window and a portion of a side wall of an Alaska Airlines Flight 1282, which had been bound for Ontario, California and suffered depressurization soon after departing, in Portland, Oregon, U.S., on Jan. 5, 2024, in this picture obtained from social media.

Instagram/@strawberrvy | Instagram/@strawberrvy Via Reute

The Federal Aviation Administration on Saturday ordered airlines to ground more than 170 Boeing 737 Max 9 aircraft for inspections, a day after after a panel on one blew out in the middle of an Alaska Airlines flight.

The emergency airworthiness directive will affect about 171 planes worldwide and applies to U.S. airlines and carriers operating in U.S. territory.

No serious injuries were reported aboard Alaska Airlines Flight 1282, according to federal safety officials. The flight returned to Portland, Oregon, shortly after takeoff on Friday after a pressurization issue was reported. Boeing delivered the plane late last year.

Images and video of Alaska’s Boeing 737 Max 9 shared on social media showed a gaping hole on the side of the plane and passengers using oxygen masks before it returned to Portland. It had been bound for Ontario, California.

Alaska Airlines overnight said it would ground its fleet of Boeing 737 Max 9 planes. United Airlines, the largest operator of the planes in the U.S., was preparing to ground dozens of its Boeing 737 Max 9 aircraft for inspections, CNBC reported earlier Saturday.

United has close to 80 of the planes in its fleet, though some of the jets have recently undergone in-depth, routine inspections.

The FAA said the inspections will take between four and eight hours per plane.

This is breaking news. Please check back for updates.

Trump Tells Iowa City To Get Over Faculty Taking pictures

While speaking in Iowa, Trump reacted to the Perry school shooting by saying that it was horrible, but it will just have to be gotten over.

Trump Tells Perry, Iowa To Get Over School Shooting

Video of Trump:

Trump on Iowa’s deadly school shooting yesterday: It’s horrible but we have to get over it pic.twitter.com/8izgCBxcAl

— Biden-Harris HQ (@BidenHQ) January 5, 2024

Trump said, “It’s horrible to see that happening. Just horrible. So surprised to see that happening here, but we’ll just have to get over it.”

Trump’s remarks came after a 17-year-old Perry High School student opened fire, killing a sixth grader and wounding four other people before taking his own life.

The difference in approach to gun violence between Biden and Trump could not be more clear. On Friday, Biden marked the 500th dangerous person who was denied access to purchasing a gun by the Bipartisan Safer Communities Act. On the same day, Donald Trump went to Iowa and told a grieving town that they had to get over a mass shooting at their local high school.

Democrats want to do something about mass shootings and gun violence, and Republicans want to do nothing. Trump is running for president for Trump. He doesn’t care about mass shootings in Iowa. His main priority is winning and avoiding a federal felony conviction.

A Special Message From PoliticusUSA

If you are in a position to donate purely to help us keep the doors open on PoliticusUSA during what is a critical election year, please do so here.

We have been honored to be able to put your interests first for 14 years as we only answer to our readers and we will not compromise on that fundamental, core PoliticusUSA value.

Jason is the managing editor. He is also a White House Press Pool and a Congressional correspondent for PoliticusUSA. Jason has a Bachelor’s Degree in Political Science. His graduate work focused on public policy, with a specialization in social reform movements.

Awards and  Professional Memberships

Member of the Society of Professional Journalists and The American Political Science Association

Eli Lilly weight reduction drug web site might not upend business

Sopa Images | Lightrocket | Getty Images

Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including its red-hot weight loss treatment Zepbound, to expand patient access. 

The company’s direct-to-consumer push announced Thursday, the first of its kind for a big drugmaker, won’t necessarily upend the pharmaceutical industry and the prescription drug supply chain alone, according to some analysts.

But other drugmakers could follow suit with their own direct-to-consumer models, according to some analysts. That could add more pressure on what many critics call a complex system for distributing, pricing and prescribing drugs in the U.S. — a structure they say has led to higher prices and fewer choices for patients.

“There’s always a possibility for disruption. I think you should never rule out any sort of disruption,” BMO Capital Markets analyst Evan Seigerman told CNBC. “I don’t think that is necessarily happening tomorrow, but I think that you should never assume that things can’t change.”

Lilly’s new platform comes as other companies move to disrupt the drug system in some way, in part as they face more political pressure to cut consumer costs and increase pricing transparency.

Those actions come as lawmakers target drug supply chain middlemen in new legislation and as the Biden administration takes its own steps to rein in prices of medications, such as by giving Medicare the power to negotiate down drug prices for the first time in its six-decade history.

Eli Lilly said its new effort — dubbed LillyDirect — aims to increase access to medicines for chronic diseases, including the highly popular weight loss drugs. 

Those treatments, which have soared in demand over the last year as they help patients shed unwanted pounds, are plagued by supply constraints and concerns about potentially harmful knockoffs. Patients also face long waitlists to meet with obesity medicine specialists who can prescribe the drugs to them, a problem Eli Lilly hopes to address, according to Seigerman.

Eli Lilly’s Zepbound won Food and Drug Administration approval just two months ago, but some analysts say it could garner more than $1 billion in sales in its first year on the market.

LillyDirect won’t significantly disrupt the industry

Eli Lilly’s site eliminates the need for a patient to visit the doctor’s office to get a prescription and, in some cases, for a pharmacy to fill it. 

But some analysts said Eli Lilly’s site alone will not significantly threaten the traditional drug distribution system, which involves a multitiered network of manufacturers, drug wholesalers, pharmacies and pharmacy benefit managers, or PBMs.

“I don’t think PBMs and the whole infrastructure that we have are going anywhere,” Seigerman told CNBC. “I think what [Eli Lilly] really did was identify some friction points in getting these products [weight loss drugs] to patients, and they’re coming up with a way to solve for that.” 

“From my understanding, it’s just that there’s no retail pharmacy where a patient is having to go hunt for that particular [drug] dose, it’s being shipped right to them,” he said of Eli Lilly’s services.

Eli Lilly’s site connects patients with an independent telehealth provider who can prescribe any FDA-approved weight loss drug or other medications for diabetes and migraines. If the prescribed treatment is Eli Lilly’s, the patient can have a third-party online pharmacy deliver it to their door. 

Patients will also receive Eli Lilly’s discounts for drugs if they qualify for the company’s savings-card programs, the company noted in a release. One program allows people with insurance coverage for Zepbound, which costs more than $1,000 per month, to pay as little as $25 out-of-pocket. Meanwhile, those whose insurance does not cover the drug may be able to pay as low as $550.

Some experts view that transparent pricing as a shot across the bow to PBMs, the largest of which are owned by CVS, UnitedHealth Group and Cigna.

Drugmakers have long complained that they give PBMs steep drug discounts in exchange for higher placement on a formulary — an insurance plan’s list of preferred medications — only for those middlemen to not pass along savings to patients. 

But Eli Lilly’s savings-card program and new site won’t cut PBMs out of the equation.

“If you still use your health insurance to get these drugs through [Eli Lilly’s] website, it’s still going to get processed by a PBM,” Jeff Jonas, a Gabelli Funds portfolio manager, told CNBC.

Patients who get drugs such as Zepbound from Eli Lilly’s site can choose to pay with cash to avoid PBMs altogether. But Bernstein analysts said in a Thursday note that they expect the “vast majority” of potential weight loss drug users to get medications through insurance. 

Other drugmakers could follow Eli Lilly

More pharmaceutical companies could adopt a similar approach to Eli Lilly’s.  

Cantor Fitzgerald analyst Louise Chen said drugmakers could benefit the most from using a direct-to-consumer pharmacy model for high-selling drugs.

“Cause of the scale of your effort, it [would] probably make sense for bigger drugs,” Chen wrote in an email to CNBC. “You get more bang for the buck and you are reaching more people.”

But Chen said it may be more difficult for a drugmaker to pursue a direct-to-consumer model with smaller, more specialized drugs, such as treatments for complex, chronic, or rare medical conditions. For example, some drugs require specialized training for administration, such as injecting or infusing a therapy into a patient’s vein through an IV. 

Drugmakers that do adopt a direct-to-consumer approach could add even more pressure on the nation’s traditional drug supply chain after other companies moved to simplify the system in recent months.

That includes CVS Health, which announced plans to overhaul its business model for pricing prescription drugs in December, adopting a model similar to billionaire Mark Cuban’s direct-to-consumer pharmacy, Cost Plus Drugs. Health-care giant Cigna also announced in November that its PBM will offer a pricing model similar to Cuban’s venture.

Cost Plus Drugs aims to drive down the price of medicines broadly by selling them at a set 15% markup over their cost, plus pharmacy fees.

That company is already shaking up the broader health-care industry: CVS suffered a blow over the summer when a major California health insurer, Blue Shield of California, announced it will no longer use the company as its PBM and instead will partner with several other businesses, including Cuban’s firm and Amazon Pharmacy. 

Winter Operating Gear Should-Haves for When It is Too Rattling Chilly Out

We independently selected these deals and products because we love them, and we think you might like them at these prices. E! has affiliate relationships, so we may get a commission if you purchase something through our links. Items are sold by the retailer, not E!. Prices are accurate as of publish time.

When it comes to running outside in the winter, I’m a big fan. I find the cold weather invigorating and refreshing, and tend to rack up more miles than I do in the summer. However, I wasn’t always this way. In fact, I used to hate moving in the colder months and dreaded it with a passion. My love for this seasonal running only started when I equipped myself with the right gear and got prepared. In order to aid others, and maybe help with tackling a new year’s resolution, I’ve put together a list of the winter running must-haves and essentials so you can start hitting the pavement ASAP. 

Of course, it depends on the outside temperature, but it’s good to start with a base layer that’s made of a material that can wick sweat away from your skin (avoid cotton, which absorbs moisture). Next, you’ll want to add layers, like a fleece or thermal jacket or vest, and possibly a windproof jacket for protection. Finally, make sure to cover exposed skin with gloves, hats, socks, and/or neck gaiters. 

And, if you’re not sure how to dress for the temp, follow the 10-Degree Rule, which means dress as if it’s 10 degrees warmer than the actual temperature. So, if it’s 30 degrees Fahrenheit outside, dress like it’s 40 degrees. This means that as your body warms up, you’ll be appropriately covered and not overheated. And, if the temperature is too low for you, maybe consider an indoor alternative.

From toasty leggings to a cozy headband, these are the must-haves you’ll need on the pavement, trails, and beyond, whether you’re a beginner or a pro. So, scroll down to check out my picks and score that new winter PR.

Biden touts minority small enterprise wins as Latino approval sags

US President Joe Biden speaks about strengthening US ports and supply chains after the International Longshore and Warehouse Union and the Pacific Maritime Association finalized a new contract covering west coast ports, in the State Dining Room of the White House in Washington, DC, on September 6, 2023.

Jim Watson | Afp | Getty Images

President Joe Biden is flaunting his investments in Black- and Latino-owned small businesses as the Latino vote slips from his grasp heading into the 2024 election year.

The president on Wednesday highlighted the parts of his Investing in America agenda aimed at supporting small businesses at Wisconsin’s Black Chamber of Commerce in Milwaukee. His remarks specifically focused on the success of “Bidenomics” for minority-owned small businesses, especially in contrast to the policies of former President Donald Trump.

“My predecessor, on his watch, women and minority-owned small businesses found themselves last in line to access emergency relief,” Biden said Wednesday.

“On my watch, energy and emergency relief went to minority-owned businesses first, not last.”

The Department of the Treasury estimates that Biden’s investments in community lenders will lead to a $50 billion increase in lending to Latino communities and a $80 billion rise for Black communities. A White House official noted before Wednesday’s event that Black small business ownership is growing faster than it has in 30 years and the creation rate of Latino small businesses is at a decade high.

Biden’s push to spotlight his support for economic equity comes amid dismal polling that shows him losing ground with Latino voters, a key demographic that helped put him in the White House in 2020.

A recent CNBC survey found that Republican front-runner Donald Trump has a 5-point lead against Biden among Latinos. Biden did maintain a significant lead against Trump with Black voters, 75% of whom said they would support the current president in a hypothetical matchup.

Biden’s effort to underscore his dedication to minority-owned small business investment is the latest bid to gain some of that ground back.

It is a strategy that has helped him before. In 2020, Biden campaigned on the idea that closing the racial economic equity gap would help heal the pandemic-stricken economy.

Read more CNBC politics coverage

As such, Biden made minority-owned business investment a central pillar of his “Build Back Better” economic platform. He pledged to create a fund with $30 billion of seed money for small businesses and to “advance racial equity.”

This rhetoric came against the backdrop of a broader reckoning over racism in policing that sparked protests nationwide. Biden’s focus on correcting racial inequity also served as a contrast to his Republican opponent, Trump.

“Every instinct Trump has is to add fuel to the fire,” Biden said at the time.

On Wednesday, Biden again differentiated his diversity stance from Trump.

“Diversity is our strength as a nation,” Biden said. “I don’t believe, as our former president said again yesterday, that immigrants are polluting our blood.”

The president was referring to Trump’s recent claim that immigrants are “poisoning the blood” of America, which the Biden campaign said “parroted Hitler.”

Biden has made headway on some of the campaign promises from 2020 and he wants voters to know it.

Earlier in 2023, Biden launched the Recompete program, which will choose 24 small businesses from economically distressed areas to receive grants of between $20 million to $50 million and 24 other recipients for grants between $250,000 and $500,000.

These grants would provide a meaningful boost to small business owners of color who face well-documented obstacles in securing capital investments and loans.

But these wins come after a year of economic woes that have exacerbated the headwinds facing minority small business owners.

A White House official noted that beyond the more deep-rooted hurdles that Black and Latino business owners face, this year has also brought “inflationary pressures.”

There are many causes for the record-high inflation that has squeezed budgets: supply chain disruptions causing product shortages, interest rate volatility boosting producer costs and pent-up demand lingering from the pandemic. Biden has pointed the finger at corporate price-gouging to explain why some consumer prices have not come down even as the economy appears to be recovering.

But so far, voters still blame the president.

The December CNBC All-America Economic Survey found that Biden’s approval ratings have fallen to an all-time low, driven in part by his handling of the economy.

For Latino voters specifically, polling has shown that the rising cost of living and jobs are top of mind heading into ballot season, which could explain why they are fleeing Biden’s camp.

Correction: Biden will address Wisconsin’s Black Chamber of Commerce in Milwaukee on Wednesday. An earlier version misstated the day.

What may occur within the Russia-Ukraine struggle in 2024?

A Ukrainian soldier is seen inside an artillery vehicle in his fighting position as Russia-Ukraine war continues in the direction of Kharkiv, Ukraine on November 20, 2023.

Diego Herrera Carcedo | Anadolu | Getty Images

At the start of 2023, hopes were high that a much-vaunted Ukrainian counteroffensive — expected to be launched in the spring — would change the dial in the war against Russia.

It didn’t, and the prospect of a breakthrough in 2024 is also unlikely, military experts and defense analysts told CNBC.

They predict intense fighting is likely to continue into the next year but say Kyiv’s forces are unlikely to launch any more counteroffensives. Russia, meanwhile, is likely to focus on consolidating the territory it has already seized, particularly in eastern Ukraine.

Away from the battlefield, military experts said that the trajectory the Russia-Ukraine war takes in 2024 will mostly be dictated thousands of miles away in the U.S., Ukraine’s largest military supporter, and whether aid declines in the run-up — and following — the U.S. presidential election.

“War is an uncertain endeavor,” retired Army Lt. Gen. Stephen Twitty, former deputy commander of the U.S. European Command, told CNBC.

“Russia can win the war, or the Ukrainians can win the war. And, as you’re seeing things now, if you really think about it, what has been achieved this year? Very little has been achieved by Russia, and you can say the same thing for the Ukrainians,” he said.

Ukrainian servicemen take part in a military training exercise not far from front line in the Donetsk region on June 8, 2023.

Anatolii Stepanov | Afp | Getty Images

“We’re in this situation now where if there’s not a clear winner, there’s going to be a stalemate, and there’s going to be, perhaps, a future frozen conflict. What can tilt the balance, in my view, is if the Ukrainians are not resupplied and they’re not re-funded and they don’t get the equipment and people that they need. Then this war could tilt to the Russians,” Twitty noted.

Expectations not met

A year ago, Ukraine’s international military support was solid with NATO pledging to support Kyiv for “as long as it takes” as it defended itself against Russia’s invasion launched in February 2022.

Over the summer, however, the challenge facing Ukraine’s forces was glaringly obvious as they struggled to break through heavily fortified Russian positions and lines of defenses along a swathe of the 600-mile-long front line across the southern and east of the country.

After liberating a handful of villages in the summer, Ukrainian and Russian forces have been caught in largely attritional battles, with neither side making significant gains.

Ukrainian military officials have conceded that hopes and expectations of a great breakthrough in the counteroffensive were not met. Still, Ukraine’s leadership says that steep losses have been inflicted on Russian forces and that its forces have made vital progress in other areas such as the Black Sea with Ukraine’s audacious attacks on Russian bases and assets in Crimea this summer prompting the Russian navy to withdraw a number of warships from Sevastopol, handing Kyiv a victory in the battle of the Black Sea.

Panorama of the city from a bird’s-eye view, shot on a drone, covered with snow on December 7, 2023 in Avdiivka, Ukraine.

Libkos | Getty Images

Weather conditions are deteriorating in Ukraine, with mud, freezing rain, snow and ice making offensive and reconnaissance operations challenging. Intense fighting continues nonetheless, and particularly around Bakhmut and Avdiivka in eastern Ukraine where Russian forces are conducting offensive operations and have made some recent, confirmed advances.

Analysts at the Institute for the Study of War noted last week that Russian forces have likely committed to offensive operations in multiple sectors of the front, during a period of the most challenging weather of the fall-winter season, “in an effort to seize and retain the initiative” before the Russian presidential elections in March 2024.

In the meantime, the ISW noted in an analysis, “Ukrainian forces establish and consolidate defensive positions to conserve manpower and resources for future offensive efforts.”

Ukrainian forces have adopted a more defensive stance as circumstances dictate; a senior army general warned last week that front-line Ukrainian troops face artillery shortages and have scaled back some military operations because of a shortfall of foreign assistance.

Aid and politics

Another year of war in Europe has undoubtedly drained Western military resources and the political appetite to maintain massive amounts of military aid for Ukraine.

Ongoing funding for Ukraine is far from secure in 2024 given the fact that the U.S. presidential election could herald a seismic change in the attitude toward and support for Kyiv.

Specifically, all eyes are on former U.S. President Donald Trump, the Republican front-runner, who cultivated close relations with his Russian counterpart Vladimir Putin during his presidency.

There are concerns that, given Trump’s previous good relations with Moscow and “America First” policy, aid for Ukraine could be shelved rapidly. Defense analysts agree that much of the outlook for Ukraine is dependent on the outcome of the U.S. vote.

“I think it’s important to understand the extent to which Ukraine is reliant on the U.S. right now, because it’s quite significantly more reliant on the U.S. than it is on the EU,” Sam Cranny-Evans, defense analyst at the Royal United Services Institute defense think tank, told CNBC.

“If the U.S. election goes in a way that is not in Ukraine’s favor, coupled with the fact that the EU is not really stepping up to the plate — it’s ammunition production is so far off what it should have been by now to give Ukraine a hope of surviving and a hope of victory — it’s not a very cheery prediction for 2024.”

Good chemistry: President Donald Trump and Russian President Vladimir Putin shake hands during a joint press conference after their summit on July 16, 2018 in Helsinki, Finland.

Chris McGrath | Getty Images News | Getty Images

Rumblings of discontent over continuing Ukraine aid have been heard in some Republican quarters for months now, as well as in Eastern Europe.

Former U.S. Ambassador to NATO Kurt Volker told CNBC he believes American and EU aid packages for Ukraine will be approved come January, saying he believed this funding would tide Ukraine over for another year, militarily. Volker said that aid packages must include more advanced weaponry for Ukraine, however, like F-16 fighter jets which have been pledged by Norway, Denmark and the Netherlands.

Ukrainian pilots are beginning their training on the jets now but it could be a number of months before they’re deployed in Ukraine. The U.S. is not providing F-16s to Ukraine but has authorized allies to provide their own jets.

“A couple of things ought to change,” Volker told CNBC. “We ought to lift restrictions on the weapons we’re providing. We still don’t provide the longest-range missiles and we still have not delivered any Western aircraft in Ukraine yet. Those things have to happen. And I think we have to try to give the Ukrainians more of a technological advantage,” he noted.

The United States has said that it will begin flight training for Ukrainian pilots on F-16 fighter jets.

Anadolu Agency | Getty Images

Volker believes that a Trump presidency might not be the catastrophe for Ukraine that is feared, but said it would make future funding uncertain.

“I doubt that even if Trump were elected that he would abandon support for Ukraine overall, because it would be a disaster for U.S. interests, and it would appear to be a failure. You’d have these images of Russians overrunning places, and brutality and so forth, so I don’t think he wants that. But it’s not clear exactly what he would do to try to end the war.”

For his part, Trump has said that he’d be able to resolve the Ukraine war “in one day” if he was reelected, saying he’d convince the leaders of Ukraine and Russia to make a deal.

More stalemate or negotiations?

Read more CNBC politics coverage

Ukraine’s Defense Ministry said last week that its main goal in 2024 is to boost its domestic defense industry in the face of uncertain future supplies from its Western allies. It has also changed conscription laws, foreseeing the need to bolster its forces, which are dwarfed in size by Russia’s but are more highly trained and equipped. Ukrainian President Volodymyr Zelenskyy said last week that the military had asked for up to 500,000 additional conscripts but said he needed to hear “more arguments” to support the sensitive and costly proposal.

With both Ukraine and Russia investing heavily in the war, it’s unlikely there will be any negotiations to end the conflict or agree to a cease-fire. Defense analysts argue that neither side would want to go into negotiations unless they’re in a position of strength and able to dictate terms.

“In the case of a Republican winning the presidential election next year, especially if that’s Donald Trump, who seems to be the front-runner, and [if] funding is decreased substantially, then there will be increased pressure on Ukraine to negotiate,” Mario Bikarski, a Europe and Russia analyst at the Economist Intelligence Unit, told CNBC.

A Ukrainian tank drives along the field on December 7, 2023 in Avdiivka, Ukraine.

Kostya Liberov | Getty Images

“Of course, Ukraine currently doesn’t want to negotiate … but given the circumstances, it will have little choice but to comply with that. And then the question also remains if Russia will be willing to negotiate because if there are signs that the West will stop supporting Ukraine, and Ukraine will be coerced into these negotiations, Russia might see this as another window of opportunity to consolidate a lot more gains.”

Defense experts told CNBC their baseline scenario for 2024 was a continuation of the current intensity of fighting but the same sense of stalemate with neither side able to progress much on the ground and take or reclaim territory.

Medicare drug value negotiations what’s forward in 2024

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.

Anna Moneymaker | Getty Images

U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the precedent for a controversial process that may affect what seniors pay for dozens of medications by the end of the decade. 

It could also be a pivotal year for the lawsuits that drugmakers – including Merck, Johnson & Johnson and Bristol Myers Squibb – have filed against the price talks. Decisions could come down in some of the cases next year, which could eventually escalate the issue to the Supreme Court.

President Joe Biden’s Inflation Reduction Act, which passed in a party-line vote last year, gave Medicare the authority to directly hash out drug prices with manufacturers for the first time in the federal program’s nearly 60-year history. 

Medicare is negotiating prices for the first round of 10 prescription drugs in a bid to make those costly treatments more affordable for older Americans. By the fall, the federal government will publish the agreed-upon prices for those medications, which will go into effect in 2026. 

Why 2024 will set a precedent for price talks

The outcomes of the talks will have huge stakes for the pharmaceutical industry, which views the process as a threat to its revenue growth, profits and drug innovation.

The final prices will determine how much revenue the companies that make the drugs can expect to lose in a few years. The figures will also give other drugmakers an idea of how much their sales could be affected if their medications are selected for future rounds of negotiations. 

But the final agreed-upon prices are also significant for patients, who will get a first look at how much money the talks will save them at a time when many older people increasingly struggle to afford medications. 

“We’re going to see how much that program is able to negotiate and it’ll give patients who are already on [the drugs] an idea of the savings they’re going to see,” said Leigh Purvis, a prescription drug policy principal at the AARP Public Policy Institute.

AARP is the influential lobby group that represents people older than 50. The organization has advocated for Medicare’s new negotiation powers.

A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020.

George Frey | Reuters

The drugs subject to the negotiations are among the top 50 with the highest spending for Medicare Part D, which covers prescription medications that seniors fill at retail pharmacies. 

In 2022, 9 million seniors spent $3.4 billion out of pocket on the 10 drugs, and some paid more than $6,000 per year for just one of the medications on the list, according to the Biden administration.

Nearly 10% of Medicare enrollees ages 65 and older, and 20% of those under 65, report challenges in affording drugs, the administration said in August. 

Medicare covers roughly 66 million people in the U.S., and 50.5 million patients are currently enrolled in Part D plans, according to health policy research organization KFF.

What the negotiation timeline looks like

The Biden administration officially kicked off the negotiation process in August when it named the first round of medications subject to the price talks. They include diabetes drugs from Merck and AstraZeneca, and blood thinners from Bristol Myers Squibb and Johnson & Johnson.

Two months later, all companies that make the drugs on the list signed agreements to participate in the negotiations, even after most of them sued the Biden administration to halt the talks. 

But the actual negotiation period will begin on Feb. 1, when the Centers for Medicare & Medicaid Services will make initial “maximum fair price” offers for each of the 10 drugs selected. CMS is required to include a justification for why the price is fair based on several factors.

That includes U.S. sales volume data, a manufacturer’s research and development costs, federal financial support for the drug’s development, data on pending or approved patent applications and exclusivities, or a period of time when a brand-name drug is protected from generic competition. 

First 10 drugs subject to price negotiations

  • Eliquis, made by Bristol Myers Squibb, is used to prevent blood clotting, to reduce the risk of stroke.
  • Jardiance, made by Boehringer Ingelheim, is used to lower blood sugar for people with Type 2 diabetes. 
  • Xarelto, made by Johnson & Johnson, is used to prevent blood clotting, to reduce the risk of stroke.
  • Januvia, made by Merck, is used to lower blood sugar for people with Type 2 diabetes.
  • Farxiga, made by AstraZeneca, is used to treat Type 2 diabetes.
  • Entresto, made by Novartis, is used to treat certain types of heart failure.
  • Enbrel, made by Amgen, is used to treat rheumatoid arthritis. 
  • Imbruvica, made by AbbVie, is used to treat different types of blood cancers. 
  • Stelara, made by Janssen, is used to treat Crohn’s disease.
  • Fiasp and NovoLog, insulins made by Novo Nordisk.

After receiving the offers, companies have a month to accept it or counter it. Negotiations end when CMS and drugmakers reach an agreement. 

If CMS rejects the counteroffer for a drug, the agency can arrange up to three meetings with the drugmaker to discuss other price options. 

CMS has to make final price offers to the manufacturers by July 15, and those companies have two weeks to accept or reject them. If drugmakers fail to agree on a price with Medicare by Aug. 1, they may be forced to pay an excise tax of up to 95% of a medication’s U.S. sales or pull all of their drug products from the Medicare and Medicaid markets. 

CMS will publish agreed-upon prices on Sept. 1. 

After the initial round of talks, CMS can negotiate prices for another 15 drugs that will go into effect in 2027 and an additional 15 that will go into effect in 2028. The number rises to 20 negotiated medications a year starting in 2029.

CMS will only select Medicare Part D drugs for the medicines covered by the first two years of negotiations. It will add more specialized drugs covered by Medicare Part B, which are typically administered by doctors, in 2028. 

How drugmaker lawsuits could develop

The legal fight between drugmakers and the Biden administration could also see crucial developments in 2024, as cases may start moving to appeals courts. 

Merck, Johnson & Johnson, Bristol Myers Squibb, AstraZeneca, Novo Nordisk, Novartis and Boehringer Ingelheim are all suing to halt the negotiation process. Each of the companies has one drug selected for negotiations. 

The industry’s biggest lobbying group, PhRMA, and the nation’s largest business lobbying organization, the U.S. Chamber of Commerce, have filed their own lawsuits. A federal judge in September denied a preliminary injunction sought by the Chamber of Commerce, which aimed to block the price talks.

All of the drugmakers and both trade groups have asked for summary judgments in their cases against the Biden administration, arguing the price talks are unconstitutional and must be struck down. 

More CNBC health coverage

Decisions in most of those cases could occur in the next six months, according to Kelly Bagby, vice president of litigation at the AARP Foundation. 

She said that regardless of what the decisions are, they will likely get appealed to federal appellate courts across the U.S. The pharmaceutical industry may be trying to obtain conflicting rulings from those appeals courts, which could fast-track the issue to the Supreme Court, Bagby added. 

“The Supreme Court would feel obliged to take the case and evaluate the constitutionality of the Inflation Reduction Act itself,” Bagby said, noting that the issue may not reach the nation’s highest court until 2025. 

Some drugmakers, such as Merck, have already confirmed they want to bring their legal battle to the Supreme Court.

Drugmakers in the lawsuits argue the negotiations would force them to sell their medicines at huge discounts, below market rates. They assert that this violates the Fifth Amendment, which requires the government to pay reasonable compensation for private property taken for public use. 

Reckitt Benckiser unit recollects probably contaminated child components powder, FDA says

Enfimil infant formula, made by Mead Johnson Nutrition Co., sits on display in a supermarket in New York, U.S.

Daniel Acker | Bloomberg News | Getty Images

Baby formula maker Reckitt Benckiser’s Mead Johnson Nutrition has voluntarily chosen to recall certain batches of baby formula powder due to possible bacterial contamination, according to the U.S. Food and Drug Administration.

The possibly impacted batches of Nutramigen Powder, an infant formula specially designed for children allergic to cow’s milk, were produced in June and distributed throughout the summer.

“Based on the limited availability of the remaining stock of this special infant formula, it is believed that much, if not all, of the products recalled in the United States have been consumed,” Reckitt said in a statement published by the FDA on Sunday.

The company said no “illnesses or adverse events” have been recorded yet but urged consumers who have purchased Nutramigen to check the bottom of the can to see if they have one of the possibly contaminated batches.

The impacted batch numbers and their corresponding can sizes are as follows:

  • ZL3FHG, 12.6 oz cans
  • ZL3FMH, 12.6 oz cans
  • ZL3FPE, 12.6 oz cans
  • ZL3FQD, 12.6 oz cans
  • ZL3FRW, 19.8 oz cans
  • ZL3FXJ, 12.6 oz cans

The possible bacterial infection in the product can cause potentially fatal infections like sepsis and meningitis, which often have symptoms like jaundice, temperature change, poor feeding, irritability, trouble breathing and unusual movements.

Bobby Lytes Defends Trina Over Beyoncé Feminine Rap Comment

Trust and believe that Bobby Lytes will always be quick to defend his cousin, Trina.

The ‘Love & Hip Hop: Miami’ star went on Instagram Live on Thursday (December 28) amid the criticism Trina is receiving for declaring Beyoncé the “No. 1 female rapper.”

Bobby Lytes Defends Trina

Taking to Instagram Live, the TV personality explained that Trina has always been a huge fan of Bey. But her decision not to mention any career female rappers may have ironically been to avoid getting backlash from certain fan groups.

“She did that to just– for this same reason,” he said in part. “Her saying Beyoncé was a light-hearted answer. But it was also for her to stay true to what she likes and who inspires her. Boom! Case closed.”

He then proceeded by saying that Trina was entitled to her own opinion and that she didn’t need to “kiss nobody’s a**” to give her honest take on female rap.

Lytes acknowledged that a particular fanbase had been extra critical of Trina’s remark, though he wouldn’t share who he was specifically referring to.

Trina Doubles Down On Naming Beyoncé Best Rapper

As previously reported, Trina recently interviewed with HipHopDX. At one point, the “Here We Go” artist shared who she thinks influenced female rap in a way that ultimately opened the doors for other women to shine.

“Yeah, Beyonce,” Trina said without hesitation. “She’s like the number one female rapper when she does rap…when you hear her do a song and its rapping involved, it’s like ‘Oh My God,’ it’s more inspiration.”

Many people contested the comment because the music industry as a whole doesn’t regard Bey as a rapper. Not to mention, several female rappers have made their mark in hip-hop these past few years, arguably helping pave the way for up-and-coming female artists in the past few years.

Still, Trina doubled down on naming Bey. After the video clip of her interview went viral, it wasn’t long before Trina hopped onto Instagram Story to issue a response.

“For the dusty crusty funky bi***es in the bacccckkk. Beyonce is the queen of rap (when she raps) and ALL other genres of music.  Now stay mad goofys I said what I said and NANN b***h gone check me.”

 

And her clapbacks didn’t end there. On Thursday, a resurfaced clip of Trina performing Nicki Minaj‘s song ‘Moment For Life’ at the 2013 BMI Awards made its rounds on X. Some people felt she could’ve shown Minaj some love in her interview, considering she had performed her song a decade prior.

When The Jasmine Brand later reposted the video on their Instagram page, Trina hopped in the comment section to stress — once again — that she had a right to her own opinion.

“Yes! Came thru and slayed it. See that’s the thing I don’t have any problems with NOBODY,” she wrote. “Im probably the only female artist that always show love to all the female artist. No jealousy. No insecurities over here. I’m actually ya favorite fave … FAVE. Don’t let that go over ya head. (Jokes up).”

She then followed up with another comment.

“What’s the REAL problem? My choice. My opinion of who I said the queen is. The f**k y’all think this is. A f***n colt. Now pls leave me alone. I hate coming on here talking to y’all. Bye”

See her comment section clapbacks here.

Social Media Continues To React

Trina became a trending topic on X, formerly known as Twitter, with people sharing their own thoughts on Trina’s response.

@Yonceforever4 tweeted.

“The way Trina said Beyonce is the queen of rap and now everyone is shaking and getting mad proves that Beyonce is literally the music industry oh Beyonce you will always be famous.”

The user @itsKARY_ wrote:

“Trina had the opportunity to name legends who pioneered female rap, and instead of listing them (or even referencing herself as one of the pioneers), she named………..Beyoncé.”

But it wasn’t all harsh criticism, as some people were quick to defend her, saying she was simply showing love to an artist she clearly admires enough to consider her favorite rapper.

And given how much love Trina has shown Beyoncé over the years, it wouldn’t necessarily be surprising.

@MrJeromeTrammel tweeted:

“Trina consistently shown love, paid homage to & worked with so many female rappers. She loves Beyonce – THAT’S HER IDOL – she was just giving Beyonce her flowers!”

“Y’all claim Trina is old, washed & irrelevant but her interview got y’all huffing and puffing & doing think pieces!

RELATED: Ain’t No Baby! Trina Denies Pregnancy Rumors Following BET Awards Performance

Trina had the opportunity to name legends who pioneered female rap, and instead of listing them (or even referencing herself as one of the pioneers), she named………..Beyoncé.

She must want a bouquet of flowers ✌🏽 pic.twitter.com/96e6AXuRY7

— kario. (@itsKARY_) December 28, 2023

I’m sorry I have to laugh because trina was doing nicki tributes when nicki was still a rookie 😭but she wasn’t the one that opened doors for the new girls? Oh okay. pic.twitter.com/YqsC9B1nb8 https://t.co/MeIoNPQV4u

— litgitte 🕷 (@MimieZaforas) December 28, 2023

Trina consistently shown love, paid homage to & worked with so many female rappers. She loves Beyonce – THAT’S HER IDOL – she was just giving Beyonce her flowers!

Y’all claim Trina is old, washed & irrelevant but her interview got y’all huffing and puffing & doing think pieces! pic.twitter.com/lSbhD497jV

— Jerome Trammel (@MrJeromeTrammel) December 28, 2023

RELATED: Foxy Brown Reacts After Nicki Minaj Breaks Their Tie For Most No. 1 Albums By A Female Rapper

Nikki Haley Implodes When Requested About Slavery

When asked what was the cause of the Civil War, Nikki Haley mentioned freedom and capitalism, but she refused to say anything about slavery.

Nikki Haley Won’t Mention Slavery

Haley was asked, “What was the cause of the Civil War?”

The presidential candidate answered, “Well, don’t come with an easy question or anything. I mean, I think the cause of the Civil War was basically how government was gonna run the freedoms and what people could and couldn’t do. What do you think the cause of the Civil War was?”

The audio is unclear but the questioner mentioned that they aren’t a presidential candidate.

Haley continued. “I mean, I think it always comes down to the role of government. We need to have capitalism. We need to have economic freedom. We need to make sure that we do all things so that individuals have the liberties so that they can have freedom of speech, freedom of religion, freedom to do or be anything they want to be without government getting in the way.”

The audio was poor, but the questioner mentioned slavery.

Haley asked, “What do you want me to say about slavery?”

Video:

Asked what caused the Civil War, Nikki Haley refuses to mention slavery: “What do you want me to say about slavery? Next question.” pic.twitter.com/cEMW3Cn9ku

— Biden-Harris HQ (@BidenHQ) December 28, 2023

 

Why Republicans Are Trying To Erase Slavery From History

Just like the Republican efforts at the state and local levels to ban books from schools and control how history is taught, Nikki Haley’s answer was a retelling of history that was intended to appease conservative white voters while ignoring the facts and rewriting American history.

Like other authoritarian movements around the world, Republicans are attempting to indoctrinate students by teaching them propaganda instead of facts.

In Florida, the State Board of Education changed the standard so that students are taught that black people benefitted from slavery and that black people were also violent during racial massacres.

Haley was afraid of alienating Republican voters who have adopted this racist view of history, so she refused to talk about the reality of slavery.

Nikki Haley Imploded Over A Simple Question

Slavery isn’t a gotcha question. Nikki Haley showed that she understands the reality of existing in Donald Trump’s Republican Party. There is no room in Trump’s party for discussions that involve historical facts and race. Republicans are tripping up because much of their base has adopted and believes Trump’s Hitler-like rhetoric.

While Donald Trump is quoting Nazis, Nikki Haley is refusing to discuss slavery. This is where the Republican Party is, as Nikki Haley revealed that she is nothing more than a more polished version of Trump’s extremism.

A Special Message From PoliticusUSA

If you are in a position to donate purely to help us keep the doors open on PoliticusUSA during what is a critical election year, please do so here.

We have been honored to be able to put your interests first for 14 years as we only answer to our readers and we will not compromise on that fundamental, core PoliticusUSA value.

Jason is the managing editor. He is also a White House Press Pool and a Congressional correspondent for PoliticusUSA. Jason has a Bachelor’s Degree in Political Science. His graduate work focused on public policy, with a specialization in social reform movements.

Awards and  Professional Memberships

Member of the Society of Professional Journalists and The American Political Science Association